Inspiration Pharmaceuticals Inc., of Laguna Niguel, Calif., said results from the Phase I portion of an ongoing IB1001 study demonstrated noninferiority of the drug in achieving overall levels of replacement factor compared to BeneFIX, an approved recombinant FIX product for hemophilia B marketed by New York-based Pfizer Inc. Those data were presented at the European Association for Haemophilia and Allied Disorders meeting in Geneva.